Advanced in Myocarditis

Chengzhi M. Zhou

State Key Laboratory Of Respiratory Diseases, 
Guangzhou, CN 
Advanced in Myocarditis
State Key Laboratory Of Respiratory Diseases, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Chengzhi Zhou practices in Guangzhou, China. Zhou is rated as an Advanced expert by MediFind in the treatment of Myocarditis. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Tissue Biopsy, and Lung Transplant.

Their clinical research consists of co-authoring 188 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of Myocarditis.

Locations

State Key Laboratory Of Respiratory Diseases, Guangzhou, China
Other Locations
Shanghai, China
Dongguan, 523808, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3

188 Total Publications

Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis.
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis.
Journal: Journal for immunotherapy of cancer
Published: August 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile